[HTML][HTML] Liver disturbances in activated phosphoinositide 3-kinase δ syndrome
G Ben-Yakov, D Kapuria, J Marko, MH Cho… - The journal of allergy …, 2018 - ncbi.nlm.nih.gov
G Ben-Yakov, D Kapuria, J Marko, MH Cho, S Pittaluga, DE Kleiner, C Koh, S Holland…
The journal of allergy and clinical immunology. In practice, 2018•ncbi.nlm.nih.govIt is a newly defined primary immunodeficiency syndrome that was previously considered
part of common variable immune deficiency (CVID). However, next-generation sequencing
defined APDS as a distinct disease in which the mechanism of hyperactive signaling and
disturbed immunological response was first described in 2013. 2 The PI3K that is
responsible for the clinical syndrome of APDS is a lipid kinase heterodimer that is a
combination of a catalytic subunit p110 and a regulatory subunit p85. These 2 subunits …
part of common variable immune deficiency (CVID). However, next-generation sequencing
defined APDS as a distinct disease in which the mechanism of hyperactive signaling and
disturbed immunological response was first described in 2013. 2 The PI3K that is
responsible for the clinical syndrome of APDS is a lipid kinase heterodimer that is a
combination of a catalytic subunit p110 and a regulatory subunit p85. These 2 subunits …
It is a newly defined primary immunodeficiency syndrome that was previously considered part of common variable immune deficiency (CVID). However, next-generation sequencing defined APDS as a distinct disease in which the mechanism of hyperactive signaling and disturbed immunological response was first described in 2013. 2
The PI3K that is responsible for the clinical syndrome of APDS is a lipid kinase heterodimer that is a combination of a catalytic subunit p110 and a regulatory subunit p85. These 2 subunits compose the PI3K complex that is involved in the signaling pathway of both B-and T-cell receptors. 2
ncbi.nlm.nih.gov
以上显示的是最相近的搜索结果。 查看全部搜索结果